Drugs / Apitegromab
Trials 7 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 24 trials | ||||||
| Phase 2 | NCT07435129 | Aug 2026 → Jun 2028 expected | facioscapulohumeral muscular dystrophy | Scholar Rock, Inc. | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07047144 | Sep 2025 → Nov 2028 expected | spinal muscular atrophy, type II, spinal muscular atrophy, type III | Scholar Rock, Inc. | Recruiting | No outcome recorded |
| Phase 2 | NCT06445075 | May 2024 → Mar 2025 | — | Scholar Rock, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT03921528 | Apr 2019 → Jan 2021 | muscular atrophy, spinal muscular atrophy, type II, spinal muscular atrophy, type III | Scholar Rock, Inc. | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT05626855 | Apr 2023 → Nov 2026 expected | muscular atrophy, spinal muscular atrophy, type II, spinal muscular atrophy, type III | Scholar Rock, Inc. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05156320 | Apr 2022 → Dec 2024 | muscular atrophy, spinal muscular atrophy, type II, spinal muscular atrophy, type III | Scholar Rock, Inc. | Completed | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT06877689 | — | spinal muscular atrophy | Scholar Rock, Inc. | No longer available | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Apitegromab | “Apitegromab, an investigational, fully human monoclonal antibody, inhibits activation of myostatin (a negative regulator of skeletal muscle growth), thereby preserving muscle mass.” PMID 38330285 ↗ Feb 2024 |
| Known as | SRK-015 | “Apitegromab (SRK-015) is an investigational, fully human immunoglobulin G4 monoclonal antibody that specifically binds to human proforms (i.e., inactive precursor forms) of...” NCT05626855 ↗ |
| Action | Inhibit | “Growth/differentiation factor 8 inhibitor” CHEMBL4594326 ↗1“inhibits activation of myostatin” PMID 38330285 ↗ Feb 2024 |
| Modality | Monoclonal antibody | “fully human anti-proMyostatin monoclonal antibody (mAb)” NCT03921528 ↗ |
| Route | Intravenous | “administered every 4 weeks by intravenous infusion” NCT03921528 ↗ |
| Target | MSTN | “Growth/differentiation factor 8 inhibitor” CHEMBL4594326 ↗ |